Autoinflammatory Awareness Month 2026: Turn Awareness into an Accountable Care Route

Awareness should reveal the pathway, not hide it

The Autoinflammatory Alliance identifies August as International Autoinflammatory Awareness Month and also uses the shorter name Autoinflammatory Awareness Month. The Alliance organized and launched this community-led international observance in 2015. The designation should not be described as a governmental proclamation.

International Autoinflammatory Awareness Month should not end with a symptom list and a social post. For a hospital or health system, the observance is a test of whether patients with recurrent or persistent inflammatory illness can move from first presentation to appropriate evaluation, specialty review, treatment access, monitoring, and long-term continuity without being left to coordinate the system themselves.

Autoinflammatory diseases are a family of disorders involving dysregulation of innate immune responses. They include inherited periodic fever syndromes, noninherited conditions, pediatric and adult-onset presentations, and patients whose inflammatory phenotype remains unclassified after an appropriate evaluation. Symptoms may cross many service lines. Fever, rash, musculoskeletal pain, abdominal or chest pain, fatigue, sensory changes, and laboratory evidence of inflammation can appear in different combinations and at different times. The same patient may enter through primary care, an emergency department, pediatrics, rheumatology, immunology, dermatology, gastroenterology, hematology, genetics, nephrology, neurology, or another specialty [2], [3], [7].

That clinical range creates an operating problem. Each individual encounter can look reasonable while the complete journey remains unreliable. One clinician excludes infection. Another addresses abdominal pain. A third evaluates a rash. A fourth orders a genetic panel. No one sees the repeated pattern, explains what an uncertain result means, or owns the next step. Awareness that only increases recognition can even increase demand without increasing the capacity needed to resolve it.

The executive opportunity is direct:

This observance gives healthcare executives an opportunity to reduce fragmented diagnostic journeys by strengthening a coordinated, equitable, life-course pathway for recurrent systemic inflammation.

The boardroom question is not whether every clinician can name every rare syndrome. It is whether the organization can recognize a pattern that warrants review, route the patient to the right expertise, preserve the history across handoffs, communicate uncertainty with respect, and measure whether the journey reaches a useful resolution.

Treat the observance as an enterprise risk signal

Autoinflammatory conditions are uncommon individually, but the pathway failures they expose are common across healthcare. The same weaknesses appear in other complex and uncommon diseases: episodic evidence that is missing at the visit, symptoms distributed across departments, uncertainty after a negative test, referral queues with no closed-loop confirmation, authorization delays, weak pediatric-to-adult handoffs, and outcomes that remain invisible once the patient leaves the originating clinic.

Executives should view five connected risks.

Diagnostic risk

A patient with recurrent inflammation may receive repeated acute evaluations without a longitudinal synthesis. Classification tools can support a structured review, but real-life performance varies by condition and population. In a 119-patient cohort, the sensitivity of Eurofever/PRINTO classification criteria differed substantially among CAPS, TRAPS, and MKD. The authors cautioned that phenotype and population-associated variation can make classification difficult [12]. Classification criteria are not the same as diagnostic criteria. A safe pathway uses them as decision support, not as an automated verdict.

Access risk

The presence of a laboratory, specialist, or medication on an organizational directory does not prove access. A 2025 service assessment across 10 Central and Eastern European countries reported that genetic testing was available in all participating countries, yet the reported turnaround was commonly three to six months. Access to disease-specific laboratory testing, reimbursement for targeted treatment, and structured transition programs varied [5]. The U.S. financing context differs, but the operating principle transfers: nominal availability can hide delays, denials, travel burden, and lost follow-up.

Treatment-reliability risk

A correct diagnosis does not guarantee reliable treatment. In one health-services study, more than half of the matched familial Mediterranean fever groups had a medication possession ratio below 80% for colchicine [13]. Possession is not ingestion, and the finding comes from one health system and one condition. Still, it exposes a measurement gap. Prescription issuance is not the same as access, use, tolerance, or continued follow-up.

Continuity risk

Many inherited conditions begin in childhood but require adult care. A retrospective cohort of 111 young people with autoinflammatory diseases found that participation in a formal transition process was associated with earlier and more regular adult follow-up. Among patients with familial Mediterranean fever, the absence of formal transition was associated with poorer disease control at baseline [10]. The study does not prove causation, but it makes a weak handoff visible as a health-system risk.

Trust risk

Repeated unexplained symptoms can erode trust. Patients may have been told that testing was normal, that symptoms did not fit a category, or that they should return only during another flare. If a new awareness message simply says “ask your doctor,” the organization transfers the coordination burden back to the person who already experienced fragmentation. Trust grows when communication is connected to a real destination, a response standard, and a defined next step.

Build one route for recurrent systemic inflammation

A reliable route does not require every hospital to become a national reference center. It does require a clear entry rule, accountable handoffs, access to consultation, and a method for managing uncertainty.

Entry: recognize a pattern worth reviewing

The entry point should help clinicians identify when recurrent or persistent systemic inflammation warrants a more coordinated evaluation. The trigger should not be a single symptom or one elevated marker. It should bring together the episode pattern, associated organ systems, objective inflammatory evidence when available, family history, age at onset, response history, and what common alternatives have already been examined.

The organization can embed a concise prompt in primary, emergency, hospital, and specialty workflows. The prompt should ask whether the patient has recurrent unexplained inflammatory episodes; whether fever, rash, musculoskeletal, gastrointestinal, neurologic, sensory, or serosal features recur together; whether inflammatory markers rise with episodes; whether symptoms began in childhood; and whether prior evaluations are dispersed across multiple records. It should route, not diagnose.

Synthesis: create a longitudinal episode record

Episodic illness is easy to miss when the patient is well at the appointment. A navigator-supported episode record can consolidate dates, duration, temperature when measured, symptoms, photographs supplied through approved channels, laboratory results, urgent visits, procedures, medication responses, and periods between episodes. This does not replace the clinical record. It makes the time pattern visible.

One accountable clinician or review team should reconcile duplicate tests, confirm which alternatives have been addressed, and identify what remains unresolved. This prevents each new specialist from restarting the journey.

Referral: route by phenotype and risk

The specialty destination will vary. Rheumatology and clinical immunology often lead the work, but gastroenterology, dermatology, genetics, hematology, nephrology, neurology, infectious disease, otolaryngology, ophthalmology, audiology, and other teams may be needed. Gastrointestinal manifestations deserve special attention because recurrent inflammatory abdominal presentations can resemble more common gastrointestinal disorders, while selected monogenic conditions carry a risk of chronic inflammatory complications [3].

Referral criteria should specify urgency, required records, initial laboratory information, and the expected response. If the system lacks local expertise, leaders should establish an external consultation route with documented turnaround, record-transfer standards, and responsibility for follow-up after the consult.

Interpretation: use genetics as one part of the pathway

Genetic testing can confirm some inherited conditions, identify a treatment-relevant mechanism, or guide family counseling. It can also return a negative result or a variant of uncertain significance. A Belgian retrospective study of 2,620 patients found that diagnostic yield rose from 15% with a 10-gene panel to 23% with a 502-gene in-silico panel. Larger panels also created greater financial and human workload [14]. More genes did not turn testing into a stand-alone answer.

Executives should ask who approves the test, who obtains consent under local policy, who interprets the result, who communicates uncertainty, who arranges counseling when needed, and what happens after a negative result. The adult literature on undifferentiated systemic autoinflammatory disease reinforces this point. Some patients have recurrent inflammatory phenotypes without a named condition or identified pathogenic variant. Their route may require repeated documentation, exclusion of common alternatives, and longitudinal specialist reassessment [2]. “No result” must not become “no owner.”

Resolution: define the next safe state

Resolution does not always mean a named genetic diagnosis. A completed pathway may result in a confirmed condition, a well-supported clinical diagnosis, an undifferentiated inflammatory phenotype under specialist follow-up, a different diagnosis, or a documented plan for reassessment if new evidence emerges. The patient should leave with an understandable summary, warning signs that require urgent clinical attention, the next appointment or monitoring plan, and a named contact for pathway questions.

Build the human infrastructure around the patient

The pathway will fail if every task is assigned to “the care team” without naming who does it. Autoinflammatory care may require a small virtual team rather than one colocated clinic, but roles still need definition.

Executive sponsor

The sponsor removes cross-department barriers, approves the service standard, secures analytic support, and reviews performance. Depending on the organization, the sponsor may be the chief medical officer, chief clinical officer, chief operating officer, or an accountable service-line leader.

Clinical pathway owner

The clinical owner maintains referral criteria, consult routes, specialty agreements, diagnostic-support content, and escalation standards. This leader should also review cases that fail the pathway, including rejected referrals, repeated emergency use before specialty review, uncertain results with no follow-up, and treatment delays.

Nurse or care navigator

The navigator assembles records, confirms appointments, supports an episode timeline, coordinates interpreter and transportation needs, tracks testing and authorization, and closes the loop after consultation. Navigation should not make clinical decisions. It should ensure that decisions already made become completed actions.

Genetic counseling and laboratory partnership

Testing needs preanalytic and postanalytic controls. The partnership should define appropriate test selection, sample requirements, expected turnaround, variant review, reanalysis policy, and communication of negative or uncertain findings. The national Belgian study shows why capacity planning must include interpretation and workload, not just the number of panels ordered [14].

Pharmacy and financial-clearance support

For therapies that require specialty authorization, refrigeration, administration training, laboratory monitoring, or recurring renewals, pharmacy and clearance staff should join the pathway early. The care team should see where the order sits, why it stalled, and who owns the next action.

Data analyst

An analyst should connect referral, scheduling, laboratory, pharmacy, encounter, and patient-experience data. Rare conditions produce small numbers, so leaders should avoid public rankings that expose identity or imply precision the data cannot support. The objective is operational learning and reliable follow-through.

Connect treatment to monitoring and exception review

The observance webpage should not tell an individual which medicine to use. It should explain what leaders must make reliable after a specialist establishes a plan.

International points to consider for four IL-1-mediated conditions organize care across diagnosis, therapy, and long-term monitoring [15]. A practical review based on those recommendations describes the need for multidisciplinary care, sustained inflammation control, treatment access, and disease-specific surveillance [8]. The scope is condition-specific. It should not be converted into a universal protocol.

From an operating perspective, every treatment plan should have six visible components:

1. The indication and accountable prescriber.
2. Authorization and acquisition status.
3. Start date and education completion.
4. Monitoring requirements and due dates.
5. A response and safety review point.
6. An escalation route for nonresponse, intolerance, missed access, or new organ findings.

Real-world registry evidence illustrates why exception review matters. In a French JIR cohort of 64 patients receiving canakinumab for FMF, MKD, or TRAPS, dosing intervals varied, treatment continuation was assessed over time, and serious adverse events required review [9]. The study was small, observational, and involved selected treated patients. It does not establish a preferred regimen. It supports the executive need for visible longitudinal monitoring and a way to distinguish intentional individualization from an unreviewed process variation.

Medication adherence deserves similar care. The health-services study of colchicine use found insufficient medication possession ratios in more than half of both matched groups [13]. Leaders should not label this as patient failure. A missed refill can reflect intolerance, confusion, cost, pharmacy supply, competing demands, or a clinical change. A useful measure pairs the signal with outreach and documents whether the barrier was resolved.

Protect the pediatric-to-adult handoff

Transition is not an administrative transfer on a birthday. It is a planned period in which the patient, family, pediatric team, and adult team establish continuity, knowledge, and a new working relationship.

The French cohort of 111 patients found earlier and more regular adult follow-up among those who participated in transition [10]. A prospective German cohort shows what the work can require. The structured pathway included a patient-history summary, assessment of disease knowledge and needs, education and counseling, coordination, and a transfer appointment. Forty-nine of 58 enrolled patients completed transfer. The mean process lasted about 315 days, and multidisciplinary consultations and coordination consumed measurable staff time [11]. The reported euro costs should not be treated as a U.S. budget. The evidence makes one point clear: transition uses capacity and must be funded.

A health system should begin preparation early enough to assess readiness, review medication and emergency plans, confirm adult specialist capacity, transfer genetic and diagnostic records, explain differences in the adult setting, and schedule the first adult visit before pediatric ownership ends. Completion means the adult team received the record, the patient attended, the plan was reconciled, and the next follow-up is scheduled.

The transition dashboard should include patients approaching the age threshold, readiness assessment status, adult clinician assignment, date of last pediatric visit, date of first adult visit, days between visits, medication continuity, and loss-to-follow-up outreach. This is a small denominator that deserves case-level review, not a yearly average alone.

Measure completed outcomes, not campaign activity

Awareness metrics can tell leaders whether people saw a message. They cannot tell leaders whether the care route worked.

An executive scorecard should separate six domains.

Reach

• Page views from the observance and related education
• Clinician education completion by relevant service line
• Referral-guide use
• Community and patient-education sessions

Reach explains exposure. It should never be presented as care completion.

Access

• Days from referral to specialist review
• Percentage of referrals returned for missing information
• Distance or travel burden where available and lawful to measure
• Interpreter need and fulfillment
• Genetic counseling and testing turnaround
• Treatment-authorization turnaround

Reliability

• Percentage of referrals with a documented next step
• Percentage of test results communicated within the service standard
• Percentage of negative or uncertain genetic results with a documented plan
• Percentage of treatment decisions that reach start, documented deferral, or documented alternative
• Percentage of monitoring tasks completed on time

Resolution

• Confirmed diagnosis
• Supported clinical diagnosis
• Undifferentiated phenotype with active specialist follow-up
• Alternative diagnosis established
• Reassessment plan documented
• Lost to follow-up or unresolved

This measure recognizes that a useful outcome is not always a named genetic condition.

Experience

• Patient understanding of the next step
• Reported coordination burden
• Confidence in whom to contact
• Respectful communication during diagnostic uncertainty
• Work, school, and caregiver disruption where the organization can collect it appropriately

Equity

Stratify selected access, reliability, and resolution measures by sex, age, language, geography, insurance category, referral source, and other locally appropriate variables. Use privacy protections when counts are small. Look for process differences, not group blame.

The board should receive a compact view: demand, median and outlier wait times, unresolved referrals, testing delays, treatment-access delays, missed transition cases, and improvement actions. Rare-disease numbers may be small, but one patient circulating for years can reveal a system defect that affects many complex-care populations.

Make public communication point to a usable destination

An observance campaign should state what the organization can actually support. Public language should explain that autoinflammatory diseases involve inappropriate innate-immune activation and may cause recurrent or persistent inflammation across body systems. It should avoid implying that every recurrent fever, rash, pain episode, or elevated laboratory result represents an autoinflammatory condition.

Every message should lead to a destination that answers four questions:

1. What pattern should prompt a conversation with a clinician?
2. Where should an existing patient or referring clinician start?
3. What information makes the review more useful?
4. What should someone expect after a referral is submitted?

The destination should include accessible language, interpreter information, emergency guidance that directs urgent concerns to appropriate services, and a clear statement that the webpage does not provide individual diagnosis or treatment advice.

Clinician communication should be more specific. A short referral guide can describe pattern recognition, the minimum record set, which department accepts the referral, how to contact the pathway for unusual presentations, and what to do if a patient is acutely ill. Emergency and urgent-care teams need an approach for documenting the episode and notifying the longitudinal clinician without delaying necessary acute evaluation.

Marketing should not claim that the system offers comprehensive autoinflammatory care unless the referral, diagnostic, pharmacy, monitoring, and transition components are operational. The safest public claim is the one the operating dashboard can verify.

The leadership standard for August and beyond

Autoinflammatory awareness becomes useful when the health system can answer a patient’s uncertainty with an organized route. Leaders do not need to promise that every case will receive a named diagnosis quickly. They should promise something they can govern: the pattern will be heard, the information will travel, the right expertise will be engaged, uncertainty will be explained, access barriers will be worked, and no result will be left without an accountable next step.

The evidence does not support one universal protocol. It supports a disciplined operating model. Patient-reported burden shows the cost of fragmented journeys [1]. Registry data make long diagnostic delays and unequal patterns visible [6]. Genetic-testing research shows that expanded technology adds yield and workload, not certainty for everyone [14]. Transition studies show that continuity requires planned labor [10], [11]. Treatment research shows that access, adherence, monitoring, and exception review continue long after a prescription is written [9], [13]. International guidance connects diagnosis, treatment, and long-term monitoring under shared ownership [15].

The executive measure of this observance is therefore not how many awareness impressions the organization creates in August. It is how many patients encounter a shorter, clearer, safer route because the organization used August to redesign the work.